<DOC>
	<DOCNO>NCT00962611</DOCNO>
	<brief_summary>The purpose study determine tolerability , maximum tolerate dose pharmacokinetics drug .</brief_summary>
	<brief_title>BAY80-6946 Open Label , Phase I Study Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Age &gt; /= 18 year . Histological cytological documentation nonhematologic , malignant solid tumor , exclude primary brain spinal tumor , history central nervous system metastasis At least one measurable lesion evaluable disease Life expectancy least 12 week ECOG Performance Status 0 , 1 2 PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ] . Lowdose aspirin permit ( &lt; /= 100 mg daily ) . Adequate bone marrow , liver renal function Ability understand sign inform consent form ; sign informed consent must obtain prior study specific procedure History cardiac disease congestive heart failure ( CHF ) &gt; NYHA Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; new onset angina within 3 month prior study entry unstable angina cardiac arrhythmia require antiarrhythmic therapy ( betablockers Digoxin permit ) . Current diagnosis type I II diabetes mellitus fast blood glucose level &gt; 125 mg/dL screening , HbA1c 7 % Active clinically serious infection &gt; Grade 2 ( NCICTCAE Version 3.0 ) History receive allogeneic organ transplant Uncontrolled seizure disorder . Use cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) allow throughout entire study . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Advanced cancer</keyword>
</DOC>